These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 32119583)
1. Can HFpEF and HFrEF Coexist? Schiattarella GG; Tong D; Hill JA Circulation; 2020 Mar; 141(9):709-711. PubMed ID: 32119583 [No Abstract] [Full Text] [Related]
2. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374 [TBL] [Abstract][Full Text] [Related]
3. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan. Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513 [TBL] [Abstract][Full Text] [Related]
4. Switching from ramipril to sacubitril/valsartan favorably alters electrocardiographic indices of ventricular repolarization in heart failure with reduced ejection fraction. Okutucu S; Sabanoglu C; Yetis Sayin B; Aksoy H; Bursa N; Oto A Acta Cardiol; 2020 Feb; 75(1):20-25. PubMed ID: 30513267 [No Abstract] [Full Text] [Related]
6. Impact of left ventricular ejection fraction on the effect of renin-angiotensin system blockers after an episode of acute heart failure: From the KCHF Registry. Yoshikawa Y; Tamaki Y; Morimoto T; Yaku H; Yamamoto E; Inuzuka Y; Ozasa N; Kitai T; Nagao K; Sato Y; Kondo H; Tamura T; Nakagawa Y; Kuwahara K; Kato T; Kimura T PLoS One; 2020; 15(9):e0239100. PubMed ID: 32925953 [TBL] [Abstract][Full Text] [Related]
7. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837 [TBL] [Abstract][Full Text] [Related]
8. Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction. Vicent L; Cinca J; Vazquez-García R; Gonzalez-Juanatey JR; Rivera M; Segovia J; Pascual-Figal D; Bover R; Worner F; Delgado-Jiménez J; Fernández-Avilés F; Martínez-Sellés M Intern Med J; 2019 Dec; 49(12):1505-1513. PubMed ID: 30887642 [TBL] [Abstract][Full Text] [Related]
9. The eligible population of the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk between 2005 and 2016. Chen X; Schaufelberger M; Fu M J Cardiovasc Med (Hagerstown); 2020 Jan; 21(1):6-12. PubMed ID: 31789711 [TBL] [Abstract][Full Text] [Related]
10. Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial. DeVore AD; Mi X; Thomas L; Sharma PP; Albert NM; Butler J; Hernandez AF; Patterson JH; Spertus JA; Williams FB; Duffy CI; McCague K; Fonarow GC J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29895587 [TBL] [Abstract][Full Text] [Related]
11. Angiotensin-Neprilysin Inhibition as a Paradigm for All? Vaduganathan M; Desai AS Curr Cardiol Rep; 2016 Nov; 18(11):115. PubMed ID: 27747488 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis. Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582 [TBL] [Abstract][Full Text] [Related]
13. Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction. Docherty KF; McMurray JJV Int J Cardiol; 2019 Apr; 281():179-185. PubMed ID: 29891240 [TBL] [Abstract][Full Text] [Related]
14. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan. Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321 [TBL] [Abstract][Full Text] [Related]
15. PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction. Docherty KF; McMurray JJV Cardiovasc Res; 2019 Nov; 115(13):e136-e139. PubMed ID: 31497841 [No Abstract] [Full Text] [Related]
16. Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction: A Meta-Analysis of Published Study Data. Beldhuis IE; Streng KW; Ter Maaten JM; Voors AA; van der Meer P; Rossignol P; McMurray JJ; Damman K Circ Heart Fail; 2017 Feb; 10(2):. PubMed ID: 28209765 [TBL] [Abstract][Full Text] [Related]
17. Heart failure with preserved ejection fraction has a better long-term prognosis than heart failure with reduced ejection fraction in old patients in a 5-year follow-up retrospective study. Kontogeorgos S; Thunström E; Johansson MC; Fu M Int J Cardiol; 2017 Apr; 232():86-92. PubMed ID: 28100428 [TBL] [Abstract][Full Text] [Related]